AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36861346
Drug: Recombinant von
RxNorm normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant von Willebrand factor (rVWF) therapy, administered as long-term routine twice weekly prophylaxis.
Trial: 36861346
Drug: Recombinant von
RxNorm normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant von Willebrand factor (rVWF) therapy.
Trial: 36861433
Drug: Oxybutynin 5
RxNorm normalized name: oxyBUTYnin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5 mg and Reboxetine 6 mg (oxy-reb)
Trial: 36861447
Drug: Platinum-free chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-free chemotherapy
Trial: 36861976
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg by mouth twice daily on day 1 followed by 200 mg by mouth twice daily on days 2 to 5)
Trial: 36861976
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral placebo with the same schedule)
Trial: 36863287
Drug: Point-of-care HCV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Point-of-care HCV RNA testing, linkage to nursing care, and peer-supported engagement/delivery of treatment
Trial: 36863386
Drug: 1-2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 g of ferric carboxymaltose intravenously
Trial: 36863386
Drug: Three tablets
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three tablets of 200 mg of oral ferrous fumarate daily
Trial: 36863390
Drug: Swallowed topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowed topical fluticasone propionate 880 μg twice per day after 6FED non-responders
Trial: 36863860
Drug: Therapists' first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapists' first impression of treatment motivation
Trial: 36864377
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health technology-based follow-up programme with monthly individualized digital conversations with a PT and activity tracker; additional digital follow-up from a nutritional specialist for those at nutritional risk.
Trial: 36864622
Drug: RO5459072 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO5459072 (100 mg twice daily; 200 mg per day)
Trial: 36864699
Drug: Two consecutive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two consecutive antagonist cycles (control)
Trial: 36864705
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme replacement therapy (ERT) with a1-glucosidase alfa
Trial: 36864830
Drug: Plasma L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma L and Z
Trial: 36864830
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of MPOV with plasma L and Z
Trial: 37997800
Drug: ACBMNCs infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACBMNCs infusion
Trial: 36865179
Drug: Therapists' care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapists' care of mental health clients, including their wellbeing and experiences in treatment.
Trial: 37774646
Drug: Intensive systolic
RxNorm normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive systolic blood pressure treatment to goal < 120 mm Hg
Trial: 36865252
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment to goal < 140 mm Hg
Trial: 36865545
Drug: NK cell-based
RxNorm normalized name: IL15-NK Cell
DrugBank: IL15-NK Cell (DB15725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK cell-based adoptive immunotherapy from HLA-haploidentical donors
Trial: 36865667
Drug: 2.5% diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5% diclofenac long duration sonophoresis (LDS) daily for 4 weeks
Trial: 36865870
Drug: Microneedling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling with topical glutathione
Trial: 36866658
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (simultaneous use of SCS that does and does not produce tingling sensation)
Trial: 36866658
Drug: Monotherapy (only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (only SCS therapy producing tingling sensation)
Trial: 36866838
Drug: Isatuximab 10
RxNorm normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab 10 mg/kg once weekly for 4 weeks followed by every 2 weeks
Trial: 36866838
Drug: Isatuximab 10
RxNorm normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab 10 mg/kg plus cemiplimab 250 mg every 2 weeks
Trial: 36866838
Drug: Isatuximab 10
RxNorm normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab 10 mg/kg plus cemiplimab 250 mg every 4 weeks
Trial: 36867504
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg apixaban
Trial: 36868179
Drug: PK-guided pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK-guided pembrolizumab administration
Trial: 36868179
Drug: History-controlled cohort
RxNorm normalized name: histolyn CYL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: History-controlled cohort (pembrolizumab 200 mg 3-weekly for more than four cycles)
Trial: 36868252
Drug: Nivolumab induction
RxNorm normalized name: nivolumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab induction treatment (240 mg every 2 weeks for 4 doses)
Trial: 36868252
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab boost (1 mg/kg plus 3 mg/kg every 3 weeks)
Trial: 36868252
Drug: Nivolumab maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab maintenance treatment
Trial: 36868252
Drug: Nivolumab induction
RxNorm normalized name: nivolumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab induction treatment
Trial: 36868261
Drug: Garadacimab (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garadacimab (400 mg loading dose followed by 200 mg monthly)
Trial: 36868591
Drug: Intensive cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cancer treatment and follow-up regimens
Trial: 36868591
Drug: Treatment burden
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment burden
Trial: 36868593
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) administered at different doses and administration intervals during laparoscopic cholecystectomy (LC)
Trial: 36868877
Drug: SCB-2019 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCB-2019 (2 doses, administered intramuscularly 21 days apart)
Trial: 36868877
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 doses, administered intramuscularly 21 days apart)
Trial: 36868914
Drug: Short-term treatment
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term treatment with the BTK inhibitor acalabrutinib and the BCL-2 inhibitor venetoclax
Trial: 36868990
Drug: ABCB5 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABCB5 treatment (3 intravenous infusions of 2 × 10)
Trial: 36868990
Drug: ABCB5 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABCB5 treatment
Trial: 36869251
Drug: Continued combination
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued combination therapy (Abatacept + Methotrexate)
Trial: 36869356
Drug: filgotinib monotherapy
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: filgotinib monotherapy
Trial: 36869356
Drug: tocilizumab monotherapy
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tocilizumab monotherapy
Trial: 36869387
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of Voriconazole (4 mg/kg)
Trial: 36869387
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of Voriconazole (6 mg/kg)
Trial: 36869387
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of Voriconazole (Vfend®) (4 mg/kg)
Trial: 36869387
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of Voriconazole (Vfend®) (6 mg/kg)
Trial: 36869392
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus music therapy (MT) during hospitalization and/or during a 6-month period post-discharge
Trial: 36869392
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus music therapy (MT)
Trial: 38040277
Drug: Oral cinacalcet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cinacalcet
Trial: 36869793
Drug: Off-Treatment
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Off-Treatment
Trial: 36869793
Drug: On-Treatment (systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-Treatment (systemic treatment)
Trial: 36870070
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (hydrocortisone, vitamin C, and thiamine)
Trial: 36870093
Drug: Ganaxolone (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganaxolone (maximum daily dose of 63 mg/kg/day if ≤28 kg or 1800 mg/day if >28 kg)
Trial: 36870358
Drug: Hydroxyurea starting
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea starting at 20 mg/kg once daily, escalated every 8 weeks by 5 mg/kg per day to maximum tolerated dose.
Trial: 36870360
Drug: Neoadjuvant sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant sintilimab monotherapy (200 mg by intravenous infusion every 21 days)
Trial: 36870360
Drug: Neoadjuvant sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant sintilimab monotherapy
Trial: 36870409
Drug: ZB-06 vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZB-06 vaginal film containing HC4-N, used as a single dose before intercourse
Trial: 36870478
Drug: Boston Bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boston Bowel Preparation Scale (BBPS)
Trial: 36870890
Drug: 1 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mcg/kg intranasal dexmedetomidine
Trial: 36870890
Drug: 2 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mcg/kg intranasal dexmedetomidine
Trial: 36870890
Drug: 3 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mcg/kg intranasal dexmedetomidine
Trial: 36870890
Drug: 4 mcg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mcg/kg intranasal dexmedetomidine
Trial: 36870941
Drug: Paclitaxel NIPEC
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel NIPEC with systemic paclitaxel and 5-fluorouracil, administered on days 1 and 8, repeated every three weeks for 4 cycles.
Trial: 36871042
Drug: AZD2811 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2811 (500 mg; Day 1; 21-day cycle with G-CSF on Day 8)
Trial: 36871042
Drug: AZD2811 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2811 (various doses from 15 to 600 mg)
Trial: 36871042
Drug: AZD2811 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2811 (various doses)
Trial: 36871101
Drug: Pfizer-BioNTech Covid-19
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer-BioNTech Covid-19 vaccine (2 doses, 21 days apart)
Trial: 36871215
Drug: Eliminating copayments
RxNorm normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eliminating copayments for high-value preventive medications (waived 30% copayment on 15 medication classes)
Trial: 36871215
Drug: Usual copayment
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual copayment (30% copayment on medications)
Trial: 36871246
Drug: Yuhan rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Yuhan rivaroxaban tablet
Trial: 36871246
Drug: Xarelto tablet
RxNorm normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Xarelto tablet
Trial: 36871424
Drug: Pembrolizumab in
RxNorm normalized name: pembrolizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab in combination with nab-paclitaxel (nP) and epirubicin/cyclophosphamide
Trial: 36871476
Drug: Shenlingcao oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenlingcao oral liquid (SOL) combined with conventional chemotherapy
Trial: 36871487
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus ipilimumab with chemotherapy (2 cycles)
Trial: 36871487
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (4 cycles)
Trial: 36872181
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg once daily (QD)
Trial: 36872181
Drug: Osimertinib 80
RxNorm normalized name: osimertinib 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib 80 mg QD
Trial: 36872337
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus apatinib and chemotherapy
Trial: 36872457
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (IC) with two cycles of 3-weekly docetaxel 75 mg/m² and concurrent chemoradiotherapy (CCRT)
Trial: 36873770
Drug: Clopidogrel monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel monotherapy after 1-month DAPT
Trial: 36873770
Drug: 12-month DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month DAPT with aspirin and clopidogrel
Trial: 36873868
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies targeting other tumor antigens or inhibitors preventing tumor antigenic escape
Trial: 36873989
Drug: Belimumab, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belimumab, dosage and duration not available
Trial: 36873994
Drug: Methylone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylone (200 mg)
Trial: 37081574
Drug: Dulaglutide 1.5
RxNorm normalized name: dulaglutide 1.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 1.5 mg once weekly
Trial: 36875061
Drug: Intrapleural administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of oncolytic vaccinia virus (1.00E+07 to 6.00E+09 PFU)
Trial: 36875061
Drug: Intrapleural administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrapleural administration of oncolytic vaccinia virus
Trial: 36876350
Drug: First-line anti-TB
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line anti-TB drugs (rifampicin, isoniazid, pyrazinamide, ethambutol)
Trial: 36876756
Drug: Transcatheter edge-to-edge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter edge-to-edge repair plus medical therapy (device group)
Trial: 36876756
Drug: Maximal doses
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal doses of guideline-directed medical therapy alone (control group)
Trial: 36876740
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid (180 mg daily)
Trial: 36876946
Drug: Telerehabilitation (TR)
RxNorm normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telerehabilitation (TR) targeting arm motor function; 36 sessions of 70 minutes each over 6 weeks, half supervised via videoconference; included functional games, exercise videos, education, and daily assessments.
Trial: 36877098
Drug: Sotatercept (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotatercept (0.3 mg/kg starting dose, 0.7 mg/kg target dose, subcutaneous every 3 weeks)
Trial: 36877259
Drug: Backup insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Backup insulin regimens generated by the BP
Trial: 36877259
Drug: Long-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting insulin dose, four-period basal insulin profile, short-acting meal doses, glucose correction factor
Trial: 36877480
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT), delivered weekly for 16 weeks
Trial: 36877502
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy (medical treatment with coronary angiography for recurrent ischemia; n=83)
Trial: 36877575
Drug: Ophthalmic involvement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic involvement at diagnosis
Trial: 36877575
Drug: Other ophthalmic
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other ophthalmic abnormalities
Trial: 36877726
Drug: Delaying factors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delaying factors (consulting traditional, private and/or multiple providers, rural residence, prehospital intravenous therapy, and prehospital overnight stays)
Trial: 36877726
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of antibiotics reserved for hospital use, intravenous therapy, and prehospital overnight stays
Trial: 36877807
Drug: Treat-to-target strategy
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target strategy (LDL-C target between 50 and 70 mg/dL)
Trial: 36877807
Drug: High-intensity statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin treatment (rosuvastatin 20 mg or atorvastatin 40 mg)
Trial: 36877964
Drug: Standard hemostatic
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hemostatic treatment
Trial: 36878237
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg every 3 weeks plus chemotherapy (paclitaxel 175 mg/m2)
Trial: 36878237
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (paclitaxel 175 mg/m2)
Trial: 36878897
Drug: Thermostable ID93
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermostable ID93 + GLA-SE vaccine
Trial: 36878897
Drug: Non-thermostable two-vial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-thermostable two-vial vaccine presentation
Trial: 36879012
Drug: anti-EGFR-ILs-dox 50
RxNorm normalized name: Anti-IL-20
DrugBank: Fletikumab (DB12356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-EGFR-ILs-dox 50 mg/m²
Trial: 36879078
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Eating Disorders (CBT-E)
Trial: 36879107
Drug: Rituximab therapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab therapy in T1DM patients
Trial: 36879129
Drug: Intravenous evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous evinacumab 15 mg/kg
Trial: 36879292
Drug: Low-calorie food
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie food images versus baseline (L vs. X)
Trial: 36879292
Drug: High-calorie food
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-calorie food images versus low-calorie food images (H vs. L)